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Background: To determine the position and dose delivery changes rules of parotid gland (PG) during the course of
intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma patients (NPC).
Materials and methods: One hundred and forty one competed tomography (CT) images from 47 NPC patients
(three images for each patient were acquired before treatment, at the 15th and 25th fraction during the treatment)
who underwent radical IMRT were selected for this study. A total of 70-76Gy at 2.12–2.3 Gy/fraction/d was given to
the GTVnx in 33 fractions. The distances between the lateral/medial aspects of PG and midline (DLM and DMM) at
the level of odontoid process were measured. The dose differences between plan and actual delivery were
calculated.
Results: The volume reductions of PGs between fractions 15 and 25 were larger than those in the first 15 fractions
(4.68 ± 3.23 cc vs. 2.46 ± 4.55 cc for the right PG and 5.96 ± 2.99 cc vs. 2.06 ± 2.99 cc for the left PG). However, the
percentage of gland volume receiving ≥30 Gy (V30) of bilateral PGs decreased more significantly in the first 15
fractions than that between fractions 15 and 25 (5.61 ± 16.04% vs. 1.14 ± 21.54% for the right PG and 6.87 ± 15.58%
vs. 0.81 ± 15.94% for the left PG). The gross tumor volume of the nasopharynx (GTVnx) decreased more significantly
in the first 15 fractions than that between the 15th and 25th fraction (8.23 ± 13.61 cc vs. 3.30 ± 8.09 cc). The DMM
of ipsilateral PGs reduced in the first 15 fractions (0.80 ± 2.96 mm) but increased between fraction 15 and 25
(−2.19 ± 3.96 mm). While ipsilateral PG shifted into target volume but shifted out target volume between fraction
15 and 25. Parotid glands V30 was correlated with GTVnx, GTVnx reduction and DMM reduction (p < 0.01).
Conclusion: Our results indicate that the reduction of GTVnx leads to the positional change of the parotid gland,
which results in more significant dose change of the parotid gland in the first 15 fractions than that between
fraction 15 and 25.
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Nasopharyngeal carcinoma (NPC) is common in southern
China [1]. Radiation therapy concurrently with chemo-
therapy is the definitive treatment for NPC [2,3]. Over
the past decade, intensity-modulated radiotherapy (IMRT)
has been widely delivered in clinic. Some patients* Correspondence: yhh93181@hotmail.com
1Department of Radiation Oncology, Affiliated Taizhou Hospital of Wenzhou
Medical University, Zhejiang 317000, China
2Laboratory of Cellular and Molecular Radiation Oncology, Affiliated Taizhou
Hospital of Wenzhou Medical University, Zhejiang 317000, China
Full list of author information is available at the end of the article
© 2015 Wang et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.receiving radiation therapy (RT) to the head and neck
have significant anatomic changes during IMRT course,
including shrinking nodal masses or primary tumors,
resolving postoperative changes/edema, and changes
in overall body habitus/weight loss [4-9]. It has been
reported that replanning by using the second CT scan
with an average interval of 19 fractions during the
course of IMRT for head and neck cancer patients
significantly reduced the normal organ dose and in-
creased the target dose coverage compared with using
the original plan on the new anatomy [8]. Our previousThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the 25th fraction in 50% of IMRT plans to avoid the
overdose to the normal sensitive structures [10,11].
We have recently reported that anatomic changes
resulted in more predominant dosimetric effects in the
first 15 fractions than those between fraction 16 and
25 [12].
Traditionally, IMRT plan was generated from single 3D
anatomy prior to treatment. For the head and neck tumor,
one of the most important roles of IMRT is to spare the
function of parotid gland, which may potentially alleviate
the degree and the rate of xerostomia [13,14]. Several
studies have reported that bilateral parotid glands had a
significantly variance of volume reduction over the treat-
ment [11,12]. A recent study [15] investigated 10 patients
with locally advanced oropharyngeal cancer treated with
contralateral parotid-sparing IMRT concurrently with
platinum-based chemotherapy. And it has been found that
ipsilateral and contralateral parotids showed a mean re-
duction in volume of 29.7% and 28.4%, respectively. Those
volume reductions resulted in significant dose changes.
To date, there are very limited studies on parotid gland
position and dose changes in IMRT of nasopharyngeal
carcinoma. Therefore, we carried out this study to evalu-
ate the rules of dose delivery changes and shift of parotid
gland during IMRT for NPC.
Methods and materials
Patients
From November 2008 and December 2011, forty-
seven NPC patients who underwent radical IMRT
were selected for this study. This study was approved
by the Institutional Review Board, and informed con-
sent was obtained from all patients before entering the
study. Patient and tumor characteristics are shown in
Table 1.
Prospective image and treatment planning
Patients were treated in the supine position and immobi-
lized with a custom thermoplastic mask covering the head,
neck and shoulders. Simulation CT scans for the initial
treatment plans (SCT-1) were performed with contrast
medium at 2.5 mm slice intervals from the skull vertex to
2 cm below the clavicles. Two re-simulation CT scans
were performed at the 15th (SCT-2) and 25th fraction
(SCT-3) of IMRT for replanning. A total of 141 CT simu-
lation scans were obtained over the study period.
The gross tumor volumes (GTVs) included the primary
nasopharyngeal tumor (GTVnx) and involved lymph
nodes (GTVnd), as shown by clinical information and
endoscopic and radiologic examinations (including CT
and MRI). The clinical target volume (CTV) included the
high-risk regions (CTV1) and the low-risk regions
(CTV2). Detailed target definition and dose constraintsfor IMRT planning have been described in our prior study
[10]. A total of 70–76 Gy (2.12–2.3 Gy/fraction), 66–70 Gy
(2.0–2.12 Gy/fraction), 60–66 Gy (1.8–2.0 Gy/fraction), and
56–60 Gy (1.7–1.8 Gy/fraction) were delivered to PTVs of
the GTVnx, GTVnd, CTV1, and CTV2, respectively, in 33
fractions with simultaneous integrated boost. All IMRT
plans were designed by inverse planning with commercial
treatment planning systems (Corvus 6.2 version, NOMOS
Corporation).
Plan 1 was the initial IMRT plan generated based on
the SCT-1. Plan 3 was the re-IMRT plan on the SCT-2.
Plan 2 was made by applying the beam configurations of
plan 1 to SCT-2 and Plan 4 was made by applying the
beam configurations of plan 3 to SCT-3 for each patient.
For each IMRT Plan, Dose-volume histograms (DVHs)
were calculated for parotid glands. The percentage of
gland volume receiving ≥ 30 Gy (V30) of PGs were eval-
uated in the four plans.
Measurement of parotid gland volume
Organs at risk (OARS) such as parotid glands were manu-
ally delineated on each axial slice of the pre-treatment
planning CT. CT-CT fusion was used to decrease the
inter-fractions step-error. Each parotid gland was outlined
on the fusion slides as described previously [16] by the
same physician/radiologist. Volumes of bilateral PGs were
compared between SCT-1 and SCT-2, SCT-2 and SCT-3
for each patient.
Measurement of parotid gland shift and transverse diameter
To quantify the positional shifts of the parotid glands,
the distances between the lateral/medial sides of PG and
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process were measured by using the methods we have
previously described [10] (Figure 1).
Data statistical analysis
The Statistical analysis was performed using software
package SPSS (version 13.0 software; SPSS Inc., Chicago,
IL). A paired- samples t-test was used to compare volumes
and shift of bilateral parotid glands between SCT-1 and
SCT-2, SCT-2 and SCT-3, and doses of bilateral parotid
glands between Plan 1 and Plan 2, Plan 3 and Plan 4. As-
sociations between continuous variables were analyzed by
Pearson’s correlation test. A p <0.05 was considered statis-
tically significant.
Results
Patients and image information
The characteristics of the patients are shown in Table 1.
A total of 141 SCTs from 47 nasopharyngeal carcinoma
patients were included this study.
Changes of target and parotid gland volume
The average volume of GTVnx was 27.37 ± 28.79 cc,
18.49 ± 21.48 cc and 16.36 ± 17.70 cc on SCT-1, SCT-2Figure 1 Definition of measurement of parotid gland shift and transver
of the parotid gland and the midline on the most superior slice with the odo
medial edge of the parotid gland to the midline on the most superior slice w
nasopharyngeal level (D1) represents the distance between the intersection p
is a posterior marginal connection for the bilateral mandibular angle [10].and SCT-3. And the average volume of GTVnd was
27.01 ± 38.06 cc, 17.75 ± 28.93 cc and 13.35 ± 23.34 cc
on SCT-1, SCT-2 and SCT-3. As shown in Table 2, the
GTVnx and GTVnd volumes had more significant reduc-
tion on the SCT-2 compared with SCT-3. The average
parotid gland volume was 21.34 ± 6.50 cc, 19.08 ± 5.50 cc,
and 13.79 ± 5.15 cc on SCT-1, SCT-2 and SCT-3. Unlike
the changes of GTVnx and GTVnd volumes, the mean
volume changes in parotid glands had more significant
decrease on the SCT- 3 compared with on SCT-2. Similar
change trends were found in comparing with the ipsilat-
eral parotid gland (IP-OG) and the contralateral parotid
gland (CON-PG).
Variation of parotid glands V30
The mean changes in parotid glands V30 had more
significant decrease on the plan 1 vs. plan 2 compared
with on plan 3 vs. plan 4. The IP-PG was more remarkable
in comparing with the CON-PG (Table 2).
Displacement of parotid gland during IMRT
Table 3 shows lateral edge and medial edge of parotid
gland shifts between SCT-1 and SCT-2, SCT-2 and
SCT-3. The lateral edge of parotid glands had shiftedse diameter. DLM represents the distance between the lateral aspects
ntoid process just still visible. DMM represents the distance between the
ith the odontoid process just still visible. The transverse diameter of the
oints on both sides of skin edges, at the level of the odontoid process. It
Table 2 Volume and dose changes of target and parotid gland
The first 15 fractions Between fraction 15 and 25
SCT-1 vs. SCT-2 SCT-2 vs. SCT-3
Volume changes Mean ± SD 95% CI p Value Mean ± SD 95% CI p Value
GTVnx 8.23 ± 13.61 4.24; 12.24 0.000 3.30 ± 8.09 0.92; 5.67 0.008
GTVnd 10.27 ± 13.37 6.02; 14.51 0.000 4.88 ± 8.41 2.19; 7.57 0.001
L-PG 2.06 ± 2.99 1.19; 2.94 0.000 5.90 ± 2.99 5.02; 6.78 0.000
R-PG 2.46 ± 4.50 1.14; 3.78 0.000 4.68 ± 3.23 3.74; 5.63 0.000
CON-PG 2.98 ± 3.50 1.80; 4.17 0.000 5.78 ± 3.00 4.77; 6.80 0.000
IP-PG 1.81 ± 3.94 0.78; 2.85 0.001 4.99 ± 3.23 4.14; 5.84 0.000
Dose changes Plan 1 vs. Plan 2 Plan 3 vs. Plan 4
(PG V30) Mean ± SD 95% CI p Value Mean ± SD 95% CI p Value
L-PG −6.87 ± 15.58 −11.45; −2.29 0.004 −0.81 ± 15.94 −5.49; 3.87 0.728
R-PG −5.61 ± 16.04 −10.32; −0.90 0.021 −1.14 ± 21.54 −7.46; 5.19 0.719
CON-PG −3.41 ± 13.44 −8.18; 1.36 0.155 0.25 ± 21.61 −7.42; 7.91 0.948
IP-PG −7.77 ± 16.76 −12.06; −3.48 0.001 −1.64 ± 17.33 −6.07; 2.80 0.464
Abbreviations: SD standard deviation, CI confindence interval, R-PG the right parotid gland, L-PG the left parotid gland, GTVnx the gross tumor volume of the
nasopharynx, GTVnd the cervical lymph node, Con-PG contralateral parotid gland, IP-PG ipsilateral parotid gland, V30 the percentage of parotid gland volume
receiving ≥ 30Gy, SCT-1 the first simulation CT scan before treatment, SCT-2 the second simulation CT scan at the fifteenth fraction of treatment, SCT-3 the third
simulation CT scan at the twenty-fifth fraction of treatment, Plan 1 the initial IMRT plan generated based on the SCT-1, Plan 2 was made by applying the beam
configurations of Plan 1 to SCT-2, Plan 3 the re-IMRT plan on the SCT-2, Plan 4 was made by applying the beam configurations of Plan 3 to SCT-3.
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edge of contralateral parotid glands shifted with an aver-
age 0.47 ± 1.47 mm (p = 0.016) on SCT-2 compared with
an average of 1.98 ± 1.83 mm (p = 0.000) on SCT-3. The
lateral edge of ipsilateral parotid glands shifted with an
average of 3.38 ± 1.53 mm (p = 0.000) on SCT-2 compared
with 1.65 ± 2.04 mm (p = 0.000) on SCT-3. The medial
edge of contralateral parotid gland shifted with an average
of −0.53 ± 2.80 mm (p = 0.000) on SCT-2 compared with
an average of −2.49 ± 3.22 mm (p = 0.000) on SCT-3. But,Table 3 Position changes of parotid gland during intensity m
The first 15 fractions
SCT1 vs. SCT2
Mean ± SD 95%CI
Positional changes (mm)
All-PG
DLM 2.65 ± 2.12 2.21; 3.09
DMM −1.25 ± 4.21 −2.12; −0.39
Con-PG
DLM 0.47 ± 1.07 0.09; 0.85
DMM −0.53 ± 2.80 −1.52; 0.46
IP-PG
DLM 3.38 ± 1.53 3.44; 4.23
DMM 0.80 ± 2.96 0.047; 1.56
Abbreviations: DLM the distance between the lateral aspects of PG and midline, DM
abbreviations are the same as those in the Table 2.
The positive and negative value for position changes means shift inside and outsidthe medial edge of ipsilateral parotid gland shifted with an
average of 0.80 ± 2.96 mm (p = 0.038) on SCT-2 compared
with an average −2.19 ± 3.96 mm shift with on SCT-3.
Thus the ipsilateral parotid gland moved to the target
volume on SCT-2.
Correlation analysis of parotid glands V30
As shown in Table 4, V30 of parotid glands are significantly
correlated with GTVnx volume (P = 0.002), GTVnx volume
reduction (P = 0.006) and DMM reduction (P = 0.000).odulated radiotherapy
Between fraction 15 and 25
SCT2 vs. SCT3
p Value Mean ± SD 95%CI p Value
0.000 1.77 ± 1.96 1.37; 2.11 0.000
0.005 −0.56 ± 3.29 −1.24; 0.11 0.100
0.016 1.98 ± 1.83 1.33; 2.63 0.000
0.281 −2.49 ± 3.22 −3.63; −1.35 0.000
0.000 1.65 ± 2.04 1.13; 2.17 0.000
0.038 −2.19 ± 3.96 −3.21; −1.18 0.000
M the distance between the medial aspects of PG and midline, The other
e, respectively.
Table 4 Correlation analysis of parotid glands V30 and
volumetric and positional variations
Pearson correlation Sig. (2-tailed)
GTVnx 0.226 0.002
GTVnx reduction −0.200 0.006
GTVnd −0.120 0.129
GTVnd reduction 0.041 0.610
PG volume 0.006 0.938
PG volume reduction 0.052 0.447
D1 0.052 0.482
D1 reduction −0.097 0.184
DLM 0.089 0.224
DLM shift −0.114 0.118
DMM 0.090 0.220
DMM shift 0.281 0.000
Abbreviations: D1 represents the transverse diameter of the nasopharyngeal
level. The other abbreviations are the sa me as the Table 2.
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GTVnd volume (P = 0.129), GTVnd volume reduction
(P = 0.610) and DLM reduction (P = 0.118).
Discussion
IMRT has been used routinely in the treatment of NPC
due to its anatomical position. The sharp dose gradient
change around the target margin in IMRT requires accur-
ate dose delivery to the target volume and critical organs.
However, it has been demonstrated that most NPC pa-
tients will experience anatomic changes, mainly including
shrinking of the primary tumor or nodal masses, parotid
glands during IMRT [8,9,11]. Furthermore, anatomic
changes could have a potential dosimetric impact when
a highly conformal IMRT technique is used.
We have previously demonstrated that replanning dur-
ing IMRT for NPC significantly improved 2-year local
regional control rate. Replanning had a profound impact
on the quality of life of NPC patients. Patients who did
not receive replanning had significantly greater problems
with speech, social contact, teeth, mouth opening, dry
mouth and sticky saliva [17]. Furthermore, it has been
reported that IMRT replanning improved the 3 years
local progression–free survival for NPC patients with
AJCC staged of late T or N, whereas patients at early stage
could not benefit from IMRT replanning by retrospectively
analyzing 33 patients [18]. Since protection of parotid
glands function directly affects the quality of life, dose vari-
ation rule of parotid gland becomes the focus of research in
the field of IMRT for nasopharyngeal carcinoma.
The changes of volume and dose of parotid gland by
repeating simulation of KV-CT scans through the IMRT
for nasopharyngeal carcinoma have been analyzed in our
previously studies. A significant larger reduction of parotidvolume was found between fraction 16 and 25 than in the
first 15 fractions. However, the dose changes of the par-
otid gland were more prominent in the first 15 fractions
than those between fractions 16 and 25 during IMRT [12].
Similarly, in the current study, we found that the variation
of parotid glands V30 was more significantly decreased
during the first 15 fractions than between fraction 16 and
25, particularly for the ipsilateral parotid glands. Several
studies have suggested that the dose change of parotid
gland may result from the parotid gland volume change
[9]. However, Some other studies suggested that the dosi-
metric changes may be related with the positional shifts of
the parotid glands during IMRT treatment [4,6]. Nishi T
et al. reported that parotid glands and the retromandibular
vein in parotid glands shifted medially an average of 4.2
mm and 2.4 mm separately at the third or fourth week of
IMRT for NPC [4]. In our present study, we further dem-
onstrated that the changes of parotid glands V30 variation
may be associated with more significant shrinkage for
GTVnx and the parotid glands moving into the high-dose
region at the first 15 fractions.
Conclusion
In conclusion, our current study indicated that shrinking
of gross tumor during IMRT treatment for NPC could
lead to ipsilateral parotid glands move into the high-dose
region at the first 15 fractions. Which subsequently leads
to considerable inaccuracies in dose delivery to ipsilateral
parotid glands during IMRT for nasopharyngeal carcin-
oma. Therefore, measurements of medial edges of parotid
gland and GTVnx volume reduction may be a potential
helpful strategy for optimizing treatment planning for
IMRT and selecting patients who could benefit signifi-
cantly from adaptive strategies.
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